Key result
Drug-eluting coronary stents carry a higher risk of very late stent thrombosis than bare-metal stents, but this does not impact long-term mortality or myocardial infarction risk.
Why the study?
Do drug-eluting coronary stents improve clinical outcomes compared with bare-metal stents in patients undergoing percutaneous coronary intervention?
Do drug-eluting coronary stents improve clinical outcomes compared with bare-metal stents in patients undergoing percutaneous coronary intervention?
Drug-eluting stents maintain a favorable net clinical benefit over bare-metal stents despite an increased risk of very late stent thrombosis.
Answers are grounded in this paper and cite their sources.
Preserves net clinical benefit of DES in PCI; leaves open optimal antiplatelet duration and surveillance needs.
Drug-eluting coronary stents are being used with increasing frequency in patients undergoing percutaneous coronary intervention. Although these stents have shown remarkably low rates of restenosis compared with their predecessors, there have been increasing concerns lately regarding their safety. Extensive data have been published that demonstrate a higher risk of very late stent thrombosis with drug-eluting stents; however, this has not had any impact on long-term mortality or the risk of myocardial infarction when compared with bare-metal stents. Their overall net clinical benefit therefore still favors their use. Recent research has led to a greater understanding of the multifactorial cause of stent thrombosis, which has enabled measures to be taken to reduce an individual patient's risk. In the future, new stent designs and new antiplatelet agents may help to reduce this risk further.
No takes yet. Share an insight, caveat, or question.
Garg et al. (2010) conducted a review in Patients undergoing percutaneous coronary intervention. Drug-eluting coronary stents vs. Bare-metal stents was evaluated. Drug-eluting coronary stents carry a higher risk of very late stent thrombosis than bare-metal stents, but this does not impact long-term mortality or myocardial infarction risk.
Synapse has enriched 10 related papers. Consider them for comparative context: